Normal Variant and Idiopathic Short Stature

Chapter

Abstract

This chapter reviews normal variant short stature, comprised of both familial short stature (FSS) and constitutional delay of growth and puberty (CDGP), as well as idiopathic short stature (ISS). FSS and CDGP are physiologic variants of short stature without an organic cause. Although ISS is not a “normal variant” of short stature, as with FSS and CDGP it does not have an underlying pathological etiology. A child with short stature requires a comprehensive history and physical examination and consideration for diagnostic studies prior to establishing these non-pathological causes of short stature. Once a diagnosis of either a normal variant short stature or ISS is established, then ongoing monitoring of auxologic parameters throughout childhood and adolescence is indicated. The Food and Drug Administration’s approval of growth hormone for ISS triggered considerable debate within the medical community in terms of costs, benefits, and the ethics of treating children with growth hormone for this form of non-pathological short stature. The treatment of normal variant short stature and ISS should be individualized for each child.

Keywords

Anthropometric measurements Aromatase inhibitor Bone age Constitutional delay of growth and puberty (CDGP) Familial short stature (FSS) GnRH agonist Growth hormone (GH) Growth velocity Idiopathic short stature (ISS) Oxandrolone Predicted adult height Provocative growth hormone stimulation test Psychosocial function Sante Adulte GH Enfant (SAGhE) Study Sex steroids Target height Testosterone 

References

  1. 1.
    Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P. Idiopathic short stature: definition, epidemiology and diagnostic evaluation. Growth Hormon IGF Res. 2008;18(2):89–110.CrossRefGoogle Scholar
  2. 2.
    Pedicelli S, Peschiaroli E, Violi E, Cianfarani S. Controversies in the definition and treatment of idiopathic short stature (ISS). J Clin Res Pediatr Endocrinol. 2009;1(3):105–15.CrossRefGoogle Scholar
  3. 3.
    Foote JM, Brady LH, Burke AL, et al. Development of an evidence-based clinical practice guideline on linear growth measurement of children. J Pediatr Nurs. 2011;26:320–1.CrossRefGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention, National Center for Health Statistics, Clinical Growth Charts, June 16, 2017. http://www.cdc.gov/growthcharts/clinical_charts.htm.
  5. 5.
    Tanner JM, Davies PSW. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107(3):317–29.CrossRefGoogle Scholar
  6. 6.
    Greulich WW, Pyle SI. Radiograph atlas of skeletal development of the hand and wrist. 2nd ed. Stanford: Stanford University Press; 1959.Google Scholar
  7. 7.
    Thodberg HH, Juul A, Lomholt J, Martin DD, et al. Adult height prediction models. The handbook of growth and growth monitoring in health and disease. New York, NY: Springer, copyright 2009; pp. 1–14.Google Scholar
  8. 8.
    Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40(4):423–41.CrossRefGoogle Scholar
  9. 9.
    Kumar V, Sundeep Hegde K, Bhat SS. The relationship between dental age, bone age and chronological age in children with short stature. Int J Contemp Dent. 2011;2(4):6–11.Google Scholar
  10. 10.
    Vallejo-Bolaños E, España-López AJ. The relationship between dental age, bone age and chronological age in 54 children with short familial stature. Int J Paediatr Dent. 1997;7(1):15–7.CrossRefGoogle Scholar
  11. 11.
    Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height at ages 2–9 years allowing for heights of parents. Arch Dis Child. 1970;45:755–62.CrossRefGoogle Scholar
  12. 12.
    Cohen P, Rogol AD, Deal C, Saenger P, Reiter EO, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93(11):4210–7.CrossRefGoogle Scholar
  13. 13.
    Soliman AT, De Sanctis V. An approach to constitutional delay of growth and puberty. Indian J Endocrinol Metab. 2012;16(5):698–705.CrossRefGoogle Scholar
  14. 14.
    Wehkalampi K, Widén E, Laine T, Palotie A, Dunkel L. Patterns of inheritance of constitutional delay of growth and puberty in families of adolescent girls and boys referred to specialist pediatric care. J Clin Endocrinol Metab. 2008;93(3):723–8.CrossRefGoogle Scholar
  15. 15.
    Palmert MR, Sedlmeyer IL. Delayed puberty: analysis of a large case series from an academic center. J Clin Endocrinol Metab. 2002;87(4):1613–20.CrossRefGoogle Scholar
  16. 16.
    Sedlmeyer IL, Hirschhorn JN, Palmert MR. Pedigree analysis of constitutional delay of growth and maturation: determination of familial aggregation and inheritance patterns. J Clin Endocrinol Metab. 2002;87(12):5581–6.CrossRefGoogle Scholar
  17. 17.
    Pugliese-Pires PN, Fortin JP, Arthur T, Latronico AC, Mendonca BB, et al. Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty. Eur J Endocrinol. 2011;165:233–41.CrossRefGoogle Scholar
  18. 18.
    Banerjee I, Hanson D, Perveen R, Whatmore A, Black GC, Clayton PE. Constitutional delay of growth and puberty is not commonly associated with mutations in the acid labile subnunit. Eur J Endocrinol. 2008;158:473–7.CrossRefGoogle Scholar
  19. 19.
    Banerjee I, Trueman JA, Hall CM, Price DA, Patel L, et al. Phenotypic variation in constitutional delay of growth and puberty: relationship to specific leptin and leptin receptor gene polymorphisms. Eur J Endocrinol. 2006;155:121–6.CrossRefGoogle Scholar
  20. 20.
    Bhangoo A, Anhalt H, Rosenfeld R. Idiopathic short stature. In: Lifshitz F, editor. Pediatric endocrinology. New York: Informa Health Care; 2007;2:51–64.Google Scholar
  21. 21.
    Guo MH, Shen Y, Walvoord EC, Miller TC, Moon JE, Hirschhorn JN, Dauber A. Whole exome sequencing to identify genetic causes of short stature. Horm Res Paediatr. 2014;82:44–52.CrossRefGoogle Scholar
  22. 22.
    Richter-Unruh A, Knauer-Fischer S, Kaspers S, Albrecht B, Gillessen-Kaesbach G, Hauffa BP. Short stature in children with an apparently normal male phenotype can be caused by 45, X/46, XY mosaicism and is susceptible to growth hormone treatment. Eur J Pediatr. 2004;163:251–6.CrossRefGoogle Scholar
  23. 23.
    Rappold G, Blum WF, Shavrikova EP, et al. Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet. 2007;44(5):306–13.CrossRefGoogle Scholar
  24. 24.
    Pereda A, Garin I, Garcia-Barcina M, et al. Brachydactyly E: isolated or as a feature of a syndrome. Orphanet J Rare Dis. 2013;8:141.CrossRefGoogle Scholar
  25. 25.
    Sisley S, Trujillo MV, Khoury J, Backeljauw P. Low incidence of pathology detection and high cost of screening in the evaluation of asymptomatic short children. J Pediatr. 2013;163(4):1045–51.CrossRefGoogle Scholar
  26. 26.
    Rosenbloom A. Sex hormone priming for growth hormone stimulation testing pre- and early adolescent children is evidence based. Horm Res Paediatr. 2011;75(1):75–80.CrossRefGoogle Scholar
  27. 27.
    Lazar L, Philip M. Is sex hormone priming in peripubertal children prior to growth hormone stimulation tests still appropriate? Horm Res Paediatr. 2010;73:299–302.CrossRefGoogle Scholar
  28. 28.
    Wyatt DT, Mark D, Slyper A. Survey of growth hormone treatment practices by 251 pediatric endocrinologists. J Clin Endocrinol Metab. 1995;80(11):3292–7.PubMedGoogle Scholar
  29. 29.
    Rose SR, Municchi G, Barnes KM, Kamp GA, et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab. 1991;73:428–35.CrossRefGoogle Scholar
  30. 30.
    Saggese G, Cesaretti G, Giannessi N, Bracaloni C, Cinquanta L, Cioni C. Stimulated growth hormone secretion (GH) in children with delays in pubertal development before and after the onset of puberty: relationship with peripheral plasma GH-releasing hormone and somatostatin levels. J Clin Endocrinol Metab. 1992;74:272–8.PubMedGoogle Scholar
  31. 31.
    Gonc EN, Kandemir N, Ozon A, Alikasifoglu A. Final heights of boys with normal growth hormone responses to provocative tests following priming. J Pediatr Endocrinol Metab. 2008;21(10):963–71.PubMedGoogle Scholar
  32. 32.
    Müeller GA, Keller A, Reich A, Hoepffner W, et al. Priming with testosterone enhances stimulated growth hormone secretion in boys with delayed puberty. J Pediatr Endocrinol Metab. 2004;17:77–83.Google Scholar
  33. 33.
    Martínez AS, Domené HM, Ropelato MG, Jasper HG, Pennisi PA, Escobar ME, Heinrich JJ. Estrogen priming effect on growth hormone (GH) provocative test: a useful tool for the diagnosis of GH deficiency. J Clin Endocrinol Metab. 2000;85(11):4168–72.PubMedGoogle Scholar
  34. 34.
    Kelnar CJ. Noonan syndrome: The hypothalamo-adrenal and hypothalamo-gonadal axes. Horm Res. 2009;72(Suppl 2):24–30.CrossRefGoogle Scholar
  35. 35.
    Anik A, Catli G, Abaci A, BÖber E. 46 XX, Male disorder of sexual development: A case report. J Clin Res Pediatr Endocrinol. 2013;5(4):258–60.CrossRefGoogle Scholar
  36. 36.
    Binder G, Schweizer R, Blumenstock G, Braun R. Inhibin B plus LH vs GnRH agonist test for distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism in boys. Clin Endocrinol. 2015;82(1):100–5.CrossRefGoogle Scholar
  37. 37.
    Segal TY, Mehta A, Anazodo A, Hindmarsh PC, Dattani MT. Role of gonadotropin-releasing hormone and human chorionic gonadotropin stimulation tests in differentiating patients with hypogonadotropic hypogonadism from those with constitutional delay of growth and puberty. J Clin Endocrinol Metab. 2009;94(3):780–5.CrossRefGoogle Scholar
  38. 38.
    Coutrant R, Biette-Demeneix E, Bouvattier C, Bouhours-Nouet N, Gatelais F, Dufresne S, Rouleau S, Lahlou N. Baseline inhibin B and anti-mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. J Clin Endocrinol Metab. 2010;95(12):5225–32.CrossRefGoogle Scholar
  39. 39.
    Adan L, Lechevalier P, Couto-Silva AC, Boissan M, Trivin C, Brailly-Tabard S, Brauner R. Plasma inhibin B and antimüllerian hormone concentrations in boys: discriminating between congenital hypogonadotropic hypogonadism and constitutional pubertal delay. Med Sci Monit. 2010;16(11):CR 511–CR517.Google Scholar
  40. 40.
    Kaissi AA, Farr S, Ganger R, Hofstaetter JG, Klaushofer K, Grill F. Treatment of varus deformities of the lower limbs in patients with achondroplasia and hypochondroplasia. Open Orthop J. 2013;7:33–9.CrossRefGoogle Scholar
  41. 41.
    Rutter MM, Smith EP. Pseudohypoparathyroidism type Ia: late presentation with intact mental development. J Bone Miner Res. 1998;13(7):1208–9.CrossRefGoogle Scholar
  42. 42.
    Donghi V, Mora S, Zamproni I, Chiumello G, Weber G. Pseudohypoparathyroidism, an often delayed diagnosis: a case series. Cases J. 2009;2:6734.CrossRefGoogle Scholar
  43. 43.
    Harrington J, Palmert M. Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: critical appraisal of available diagnostic tests. J ClinEndocrinol Metab. 2012;97:3056–67.CrossRefGoogle Scholar
  44. 44.
    Rosenfeld RG, Northcraft GB, Hintz RL. A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. Pediatr. 1982;69(6):681–7.Google Scholar
  45. 45.
    Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med. 1988;319:1563–7.CrossRefGoogle Scholar
  46. 46.
    Palmert MR, Dunkel L. Delayed puberty. N Engl J Med. 2012;366:443–53.CrossRefGoogle Scholar
  47. 47.
    Crowne EC, Wallace WH, Moore C, Mitchell R, et al. Effect of low dose oxandrolone and testosterone treatment on the pituitary-testicular and GH axes in boys with constitutional delay of growth and puberty. Clin Endocrinol. 1997;46(2):209–16.CrossRefGoogle Scholar
  48. 48.
    Hero M, Wickman S, Dunkel L. Treatment with aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of growth and puberty. Clin Endocrinol. 2006;64(5):510–3.CrossRefGoogle Scholar
  49. 49.
    Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90(12):6396–402.CrossRefGoogle Scholar
  50. 50.
    Salehpour S, Alipour P, Razzaghy-Azar M, Ardeshirpour L, et al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr. 2010;74(6):428–35.CrossRefGoogle Scholar
  51. 51.
    NIH, U.S. National Library of Medicine, Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature. December 18, 2017. https://clinicaltrials.gov/ct2/show/NCT01248416.
  52. 52.
    Hero M, Toiviainen-Salo S, Wickman S, Mäkitie O, Dunkel L. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res. 2010;25(7):1536–43.CrossRefGoogle Scholar
  53. 53.
    Karmazin A, Moore WV, Popovic J, Jacobson JD. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab. 2005;18(3):285–93.CrossRefGoogle Scholar
  54. 54.
    Maurus N, Bell J, Snow BG, Winslow KL. Sperm analysis in growth hormone-deficient adolescents treated with aromatase inhibitor: comparison with normal controls. Fertil Steril. 2005;84(1):239–42.CrossRefGoogle Scholar
  55. 55.
  56. 56.
    Hintz RL, Attie KM, Baptista J, Roche A, For the Genentech Collaborative Group. Effect of growth hormone treatment on adult height of children with idiopathic short stature. N Engl J Med. 1999;340(7):502–7.CrossRefGoogle Scholar
  57. 57.
    MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. J Clin Endocrinol Metab. 1996;81(5):1806–9.PubMedGoogle Scholar
  58. 58.
    Bryant J, Baxter L, Cave CB, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev. 2007;18(3):CD004440.Google Scholar
  59. 59.
    Leschek EW, Rose SR, Yanovski JA, Troendle JF, et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(7):3140–8.CrossRefGoogle Scholar
  60. 60.
    Finkelstein BS, Imperiale TF, Speroff T, et al. Effect of growth hormone therapy on height in children with idiopathic short stature: a metanalysis. Arch Pediatr Adolesc Med. 2002;156:230–40.CrossRefGoogle Scholar
  61. 61.
    Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. 2011;342(11):c7157.CrossRefGoogle Scholar
  62. 62.
    Allen DB. Safety of growth hormone treatment of children with idiopathic short stature: the US experience. Horm Res Paediatr. 2011;76(Suppl 3):45–7.CrossRefGoogle Scholar
  63. 63.
    Kamp GA, Waelkens JJ, de Muinck Keizer-Schrama SM, Delemarre-van de Waal HA, Verhoeven-Wind L, Zwinderman AH, Wit JM. High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature. Arch Dis Child. 2002;87(3):215–20.CrossRefGoogle Scholar
  64. 64.
    Albertsson-Wikland K, Aronson AS, Gustafsson J, et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab. 2008;93(11):4342–50.CrossRefGoogle Scholar
  65. 65.
    Wit JM, Reiter EO, Ross JL, Saenger PH, Savage MO, Rogol AD, Cohen P. Idiopathic short stature: management and growth hormone treatment. Growth Horm IGF Res. 2008;18(2):111–35.CrossRefGoogle Scholar
  66. 66.
    Wit JM, Rekers-Mombarg LT, Cutler GB, et al. Growth hormone(GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr. 2005;146(11):45–53.CrossRefGoogle Scholar
  67. 67.
    Lee JM, Davis MM, Clark SJ, Hofer TP, Kemper AR. Estimated cost-effectivenss of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med. 2006;160(3):263–9.CrossRefGoogle Scholar
  68. 68.
    Ashworth M, Clement S, Wright M. Demand, appropriateness and prescribing of ‘lifestyle drugs’: a consultation survey in general practice. Fam Pract. 2002;19(3):236–41.CrossRefGoogle Scholar
  69. 69.
    Kamp GA, Mul D, Waelkens JJ, et al. A randomized controlled trial of three years of growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. J Clin Endocrinol Metab. 2001;86(7):2969–75.PubMedGoogle Scholar
  70. 70.
    van Gool SA, Kamp GA, Visser-van Balen H, Mul D, Waelkens JJJ, et al. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J Clin Endocrinol Metab. 1997;92(4):1402–8.CrossRefGoogle Scholar
  71. 71.
    Poyrazoğlu S, Günöz H, Darendeliler F, Saka N, Bundak R, Bas F. Constitutional delay of growth and puberty: from presentation to final height. J Pediatr Endocrinol Metab. 2005;18(2):171–9.CrossRefGoogle Scholar
  72. 72.
    Stabler B. Impact of growth hormone therapy on quality of life along the lifespan of GH-treated patients. Horm Res. 2001;56(Suppl 1):55–8.PubMedGoogle Scholar
  73. 73.
    Stabler B, Siegel PT, Clopper RR, Stoppani CE, Compton PG, Underwood LE. Behavior change after growth hormone treatment of children with short stature. J Pediatr. 1998;133:366–73.CrossRefGoogle Scholar
  74. 74.
    Voss L, Walker J, Lunt H, Wilkin T, Betts P. The Wessex growth study: first report. Acta Paediatr Scand. 1989;340(Suppl):65–72.CrossRefGoogle Scholar
  75. 75.
    Downie AB, Mulligan J, Stratford RJ, Betts PR, Voss LD. Are short normal children at a disadvantage? The Wessex growth study. BMJ. 1997;314:97–100.CrossRefGoogle Scholar
  76. 76.
    Ulph F, Betts P, Mulligan J, Stratford RJ. Personality functioning: the influence of stature. Arch Dis Child. 2004;89(11):17–21.CrossRefGoogle Scholar
  77. 77.
    Sandberg DE, Brook AE, Campos SP. Short stature: a psychosocial burden requiring growth hormone therapy? Pediatrics. 1994;94:832–40.PubMedGoogle Scholar
  78. 78.
    Kranzler JH, Rosenbloom AL, Proctor B, Diamond F, Watson M. Is short stature a handicap? A comparison of the psychosocial functioning of referred and nonreferred children with normal short stature and children with normal stature. J Pediatr. 2000;136(1):96–102.CrossRefGoogle Scholar
  79. 79.
    Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97(2):416–25.CrossRefGoogle Scholar
  80. 80.
    Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, et al. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab. 2012;97(1):68–72.CrossRefGoogle Scholar
  81. 81.
    Savendahl L, Maes M, Albertsson-Wikland K, Borgström B, et al. Long-term mortality and causes of death in isolated GHD, ISS and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97(2):E213–7.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Massachusetts Medical School, UMASS Memorial Children’s Medical Center, UMASS Memorial Health CareWorcesterUSA
  2. 2.Pediatrics and Cell & Developmental BiologyUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations